Encouraging Preliminary Results in Myelofibrosis Trial Lead to Enhancements in Phase 2

Based on positive phase I data from the MANIFEST trial of BET inhibitor CPI-0610 as monotherapy and in combination with ruxolitinib in patients with myelofibrosis, phase II will stratify patients into three cohorts: transfusion and non-transfusion dependent patients and JAK1/2 inhibitor–naive patients.